Key facts
- This page summarizes Yong Ben's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Oct 2026, 16:11.
Yong Ben - 01 Oct 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)
- Reporting relationship
- Chief Med & Dev Officer
- Issuer ticker
- BBOT
- Reported as of
- 01 Oct 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Oct 2026, 16:11:29 UTC
- Prior SEC filing
- 15 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aaron Chan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Yong Ben filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 05 Oct 2026.
Change
- Previous filing in this sequence was filed on 15 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001967669
Primary reporting owner
Ben Yong
- Relationship
- Chief Med & Dev Officer
- Address
- BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
- Signature
- /s/ Aaron Chan, Attorney-in-Fact
- Signature date
- 05 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBOT
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -1,047
- Change %
- -2.3%
- Price
- $3.94*
- Shares after
- 43,529
- Date
- 01 Oct 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.